DBV Technologies to Highlight New Clinical Data at ACAAI 2022
09 Novembro 2022 - 3:30AM
Montrouge, France, November 9, 2022
DBV
Technologies to Highlight New
Clinical Data at ACAAI 2022
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that new clinical data
on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic
toddlers ages 1 to 3 years will be presented at the American
College of Allergy, Asthma & Immunology (ACAAI) Annual
Scientific Meeting, which is being held November 10-14, 2022, in
Louisville, KY. Two abstracts have been accepted, including one
oral presentation and one poster presentation. These presentations
will be available on DBV’s website, www.dbv-technologies.com,
following the conclusion of the meeting for those who are unable to
attend. DBV will also host a booth in the ACAAI Exhibit Hall from
Friday, November 11, through Sunday, November 13.
This year’s meeting will also feature a “Product
Theater” on the Evolution of the Prevention and Treatment of Peanut
Allergy in Young Children. Professors Gideon Lack, M.D., and J.
Andrew Bird, M.D., will engage in a lively discussion around how
evidence from peanut allergy prevention and treatment studies in
young children may impact current and future clinical practice. The
Product Theater is scheduled for Saturday, November 12, from 9:35
a.m. to 10:00 a.m. EST in the Exhibit Hall, Upper Concourse.
DBV is the sole sponsor, via an independent
educational grant, of the International Food Allergy Symposium, a
full-day symposium that kicks off ACAAI. Leading experts from
around the world will present various topics related to food
allergy, including epidemiology, diagnostics, prevention and
treatment. The symposium is scheduled for Thursday, November 10,
from 8:00 a.m. to 6:00 p.m. EST. The Company is also sponsoring the
31st Annual FIT Bowl, a game show-type competition that tests the
knowledge of participating teams from training programs around the
country. The competition is set to be held on Saturday, November
12, from 5:30 p.m. to 7:30 p.m. EST in Commonwealth Ballroom Salons
1 & 2.
“There is a significant unmet need that persists
among toddlers suffering from peanut allergy. The additional data
being presented at this year's ACAAI meeting highlight the
potential for Viaskin Peanut as a treatment option for this young
and vulnerable patient population if approved,” said Dr. Pharis
Mohideen, Chief Medical Officer of DBV Technologies.
“We continue to work towards seeking approval to
bring this novel treatment option to market as
expeditiously as possible.”
Viaskin Peanut is the Company’s lead product
candidate designed to reduce the risk of allergic reactions due to
accidental exposure to peanuts. An investigational, non-invasive,
once-daily epicutaneous patch, Viaskin Peanut seeks to deliver
microgram quantities of peanut antigen to re-educate the immune
system. The safety and efficacy of Viaskin Peanut have not yet been
established by the U.S. Food and Drug Administration or the
European Medicines Agency. Viaskin is DBV’s proprietary approach to
epicutaneous immunotherapy (EPIT™), a method of delivering
biologically active compounds to the immune system through the
skin.
DBV
Abstracts:
Oral Presentation
“EPITOPE Study Results: Phase 3,
Randomized, Double-blind, Placebo-controlled Study of Epicutaneous
Immunotherapy in Peanut-allergic Toddlers” will be
presented by Matthew Greenhawt, M.D., M.Sc., MBA, FACAAI,
Children’s Hospital Colorado, Aurora, CO.
- Presentation ID: D019
- Session Title: Distinguished
Industry Oral Abstracts - Session B
- Presentation Date: Saturday,
November 12
- Presentation Time: 4:30 p.m. – 5:30
p.m. EST
- Presentation Location: Room M104 -
M107
Poster Presentation
“Reduction in Reaction
Severity Following 12 Months of Epicutaneous Immunotherapy with
Peanut Patch in Toddlers” will be
presented by Terri Brown-Whitehorn, M.D., Children’s Hospital of
Philadelphia, Philadelphia, PA.
- Presentation ID: P183
- Session Title: ePoster – Meet the
Author
- Presentation Date: Friday, November
11
- Presentation Time: 3:00 p.m.
EST
- Presentation Location: Exhibit Hall
(Upper Concourse), Monitor 16
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding the therapeutic potential of
Viaskin™ Peanut as a treatment for peanut-allergic children and the
potential benefits of EPIT™. These forward-looking statements and
estimates are not promises or guarantees and involve substantial
risks and uncertainties and may be impacted by market conditions as
well as other risks and uncertainties set forth in DBV
Technologies’ regulatory filings with the Autorité des Marchés
Financiers (“AMF”), DBV Technologies’ filings and reports with the
U.S. Securities and Exchange Commission (“SEC”), and future filings
and reports made with the AMF and SEC. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media Contact Angela
MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV
Technologies.
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024